Upmc

Health care provider and insurer

Based in PA

🤖

AI Overview

With $1.5M in lobbying spend across 17 quarterly filings, Upmc is a significant lobbying presence.

$1.5M
Total Lobbying Spend
17
Quarterly Filings
1
Lobbying Firms Used
5
Individual Lobbyists

Spending by Year

YearLobbying Spend
2021$130K
2022$450K
2023$360K
2024$270K
2025$270K

Lobbying Firms

FEDERAL HEALTH POLICY STRATEGIES

What They Lobby For

  • Medicare billing issues Medicare legislative and regulatory issues
  • H.R. 5376, Build Back Better Act; issues related to proposed CMS/HHS rules governing the hospital inpatient and outpatient prospective payment systems and the physician fee schedule; issues related to operation of the CARES Act Provider Relief Fund
  • H.R. 5376, Build Back Better Act; issues related to proposed CMS/HHS rules governing the hospital inpatient and outpatient prospective payment systems and the physician fee schedule; issues related to operation of the CARES Act Provider Relief Fund; S. 610 Protecting Medicare and American Farmers from Sequester Cuts Act
  • H.R. 5376, Build Back Better Act; issues related to proposed CMS/HHS rules governing the hospital inpatient and outpatient prospective payment systems and the physician fee schedule; issues related to operation of the CARES Act Provider Relief Fund; S. 610 Protecting Medicare and American Farmers from Sequester Cuts Act; H.R. 2471, Consolidated Appropriations Act, 2022; H.R. 4407/S. 1568 TRAIN Act
  • H.R. 5376, Build Back Better Act; issues related to proposed CMS/HHS rules governing the hospital inpatient and outpatient prospective payment systems and the physician fee schedule; issues related to operation of the CARES Act Provider Relief Fund; S. 1568/H.R. 4407 TRAIN Act
  • H.R. 5376, Inflation Reduction Act; issues related to proposed CMS/HHS rules governing the hospital inpatient and outpatient prospective payment systems and the physician fee schedule; issues related to operation of the CARES Act Provider Relief Fund; S. 1568/H.R. 4407 TRAIN Act H.R. 4040, Advancing Telehealth Beyond COVID-19 Act
  • H.R. 5376, Inflation Reduction Act; issues related to proposed CMS/HHS rules governing the hospital inpatient and outpatient prospective payment systems and the physician fee schedule; issues related to operation of the CARES Act Provider Relief Fund; S. 1568/H.R. 4407 TRAIN Act H.R. 4040, Advancing Telehealth Beyond COVID-19 ActH.R. 2167, Consolidated Appropriations Act of 2023
  • H.R. 5376, Inflation Reduction Act; issues related to proposed CMS/HHS rules governing the hospital inpatient and outpatient prospective payment systems and the physician fee schedule; issues related to operation of the CARES Act Provider Relief Fund; S. 1568/H.R. 4407 TRAIN Act H.R. 4040, Advancing Telehealth Beyond COVID-19 Act H.R. 2167, Consolidated Appropriations Act of 2023
  • Issues related to CMS final rules governing Outpatient Protective Payment Systems (OPPS), Physician Fee Schedule (PFS) and 340B remedies; issues related to hospital transparency and health care consolidation under review by House Energy and Commerce Committee, House Ways and Means Committee, and Senate Finance Committee; issues related to cancer drug shortages; issues related to proposals affecting site of service payment differentials; H.R. 5378, Lower Costs, More Transparency Act; S. 2840, Bipartisan Primary Care and Workforce Act; issues related to cancer treatment and radiation oncology.
  • Issues related to CMS proposed rules on improving organ transplant access; issues related to proposals affecting site of service payment differentials; H.R. 5378, Lower Costs, More Transparency Act; S. 2840, Bipartisan Primary Care and Workforce Act; issues related to mandatory program extender policies including delaying Medicaid Disproportionate Share Hospitals (DSH) reductions; issues related to Health Resources and Services Administration (HRSA) 340B program.

Related Investigations

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.